Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
The purpose of this clinical trial is to evaluate the performance of the sickle cell disease (SCD) electronic diary in people with SCD who are on treatment that will change SCD and those not on such a treatment.
> 18 Years
Background: People with sickle cell disease (SCD) have problems with their heart, brain, kidneys, liver, and lungs as they age.
18 Years - 100 Years
Background: Sickle cell disease (SCD) is an inherited disorder of the blood.
The investigators will conduct a hybrid type 1 effectiveness implementation trial to assess the effectiveness of acupuncture and guided relaxation on 360 people with Sickle Cell Disease (SCD), while observing and gathering information on implementation in three health systems: University of Illinois Hospital & Health Sciences System, University of Florida Health, and Duke University Health Systems.
Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births.
4 Years - 65 Years
This registry is an observational study designed to evaluate the effect of Oxbryta in individuals with SCD in a real-world setting.
> 4 Years
Background: Sickle Cell Disease (SCD) causes blood cells form a crescent shape.
18 Years - 120 Years
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.
Background: Blood disorders like sickle cell disease and malaria affect many people around the world.
18 Years - 70 Years
